TY - JOUR
T1 - Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma
T2 - Combination immunotherapy
AU - Vathiotis, Ioannis A.
AU - Johnson, Jennifer M.
AU - Argiris, Athanassios
N1 - Funding Information:
Dr Johnson discloses that she has received research funding from Merck Serono, Bristol Myers Squibb and AstraZeneca. Dr Argiris discloses that he has received consulting or advisory fees from Merck Serono, Bristol Myers Squibb, Roche, Debiopharm Group, Aspyrian Therapeutics and Seattle Genetics. He has also served in the speakers’ bureau for Merck Serono and Bristol Myers Squibb. Finally, he has received research funding from Genentech/Roche and Bristol Myers Squibb.
Funding Information:
Dr Ioannis A Vathiotis was supported by a scholarship from the Hellenic Society of Medical Oncologists (HESMO).
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/6
Y1 - 2021/6
N2 - Anti-programmed cell death protein 1 immunotherapy has become the new standard in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the population that benefits is small, warranting drug combinations and novel approaches. HNSCC is a profoundly immunosuppressive disease, characterized by the interplay among different immune regulatory pathways. As clinical trials evaluating immunotherapy combinations in patients with HNSCC have started producing preliminary results, preclinical evidence on potential new targets for combination immunotherapy continues to accumulate. This review summarizes emerging clinical and preclinical data on immunotherapy combinations for the treatment of HNSCC.
AB - Anti-programmed cell death protein 1 immunotherapy has become the new standard in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the population that benefits is small, warranting drug combinations and novel approaches. HNSCC is a profoundly immunosuppressive disease, characterized by the interplay among different immune regulatory pathways. As clinical trials evaluating immunotherapy combinations in patients with HNSCC have started producing preliminary results, preclinical evidence on potential new targets for combination immunotherapy continues to accumulate. This review summarizes emerging clinical and preclinical data on immunotherapy combinations for the treatment of HNSCC.
KW - HNSCC
KW - Immunotherapy
KW - PD-1
KW - PD-L1
UR - http://www.scopus.com/inward/record.url?scp=85103643209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103643209&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2021.102192
DO - 10.1016/j.ctrv.2021.102192
M3 - Review article
C2 - 33819755
AN - SCOPUS:85103643209
VL - 97
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
M1 - 102192
ER -